GlassScriptPhysician profile
Rajiv Agrawal
NPI 1659392496
$7,123.52
in general payments reported to CMS, 2019-2025
39 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $458 · 2021: $843 · 2022: $1,460 · 2023: $1,394 · 2024: $901 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,505.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $707.66 | 2020-2025 | Airsupra, Breztri |
| Abbott Laboratories | $556.34 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $517.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $511.05 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $484.83 | 2019-2025 | |
| Abbvie INC. | $423.15 | 2021-2025 | Ubrelvy, Rinvoq |
| Novo Nordisk INC | $414.51 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $261.99 | 2022-2025 | Repatha, Krystexxa, Repatha |
| Neurocrine Biosciences, INC. | $191.52 | 2022-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $183.34 | 2022-2025 | Rexulti |
| Vifor Pharma, INC. | $144.50 | 2019 | |
| Amarin Pharma, INC. | $119.04 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $117.93 | 2023 | Dupixent |
| Verona Pharma, INC. | $89.08 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $84.18 | 2021-2025 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.08 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $77.37 | 2022 | |
| Janssen Biotech, INC. | $70.97 | 2024-2025 | Tremfya, Stelara, Simponi |
| Horizon Therapeutics Plc | $67.00 | 2022-2023 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $58.57 | 2021 | |
| Acadia Pharmaceuticals INC | $52.46 | 2023-2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $42.54 | 2019 | |
| Exact Sciences Corporation | $36.81 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $33.31 | 2021-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $30.90 | 2019 | |
| Currax Pharmaceuticals LLC | $28.81 | 2023 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $25.32 | 2023 | |
| Lundbeck LLC | $24.05 | 2025 | Rexulti |
| Phadia US INC. | $23.36 | 2019 | |
| Merck Sharp & Dohme LLC | $23.25 | 2020 | |
| Idorsia Pharmaceuticals US INC | $22.90 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $19.76 | 2025 | Edarbyclor |
| Pulmonx Corporation | $19.14 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Dexcom, INC. | $16.39 | 2021 | |
| Allergan, INC. | $16.17 | 2019 | |
| Bausch Health US, LLC | $14.75 | 2019 | |
| Inari Medical, INC. | $14.04 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shire North American Group INC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.